TOP1
Basic information
Region (hg38): 20:41028822-41124487
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TOP1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 9 | |||||
missense | 8 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 7 | 5 | 5 |
Variants in TOP1
This is a list of pathogenic ClinVar variants found in the TOP1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
20-41061435-C-T | not specified | Uncertain significance (Jul 07, 2024) | ||
20-41061479-G-A | Benign (Dec 31, 2019) | |||
20-41076256-C-T | Benign (Dec 31, 2019) | |||
20-41077586-G-A | not specified | Uncertain significance (Sep 27, 2022) | ||
20-41080168-G-A | not specified | Uncertain significance (Oct 21, 2024) | ||
20-41081215-A-G | not specified | Uncertain significance (May 08, 2024) | ||
20-41084482-C-T | Benign (Nov 20, 2018) | |||
20-41084486-A-C | not specified | Uncertain significance (Jul 09, 2021) | ||
20-41084539-G-A | TOP1-related disorder | Likely benign (Jul 25, 2019) | ||
20-41084548-A-G | TOP1-related disorder | Benign (Dec 31, 2019) | ||
20-41097224-A-C | not specified | Uncertain significance (Jul 05, 2023) | ||
20-41098228-A-T | not specified | Uncertain significance (Sep 11, 2024) | ||
20-41098319-G-A | not specified | Uncertain significance (Mar 15, 2024) | ||
20-41100127-G-A | Benign (Oct 17, 2018) | |||
20-41100181-C-T | Likely benign (Dec 31, 2019) | |||
20-41101226-C-T | not specified | Uncertain significance (Jun 11, 2024) | ||
20-41101262-A-T | Autism spectrum disorder | association (-) | ||
20-41101297-G-A | DNA topoisomerase I, camptothecin-resistant | Pathogenic (Jul 01, 2002) | ||
20-41112919-C-T | TOP1-related disorder | Likely benign (Apr 09, 2019) | ||
20-41114060-C-T | not specified | Uncertain significance (Dec 19, 2023) | ||
20-41114067-A-G | not specified | Uncertain significance (Nov 07, 2024) | ||
20-41114115-A-G | - | no classification for the single variant (-) | ||
20-41116318-G-G | - | no classification for the single variant (-) | ||
20-41118221-T-C | TOP1-related disorder | Likely benign (Oct 28, 2019) | ||
20-41118228-A-G | not specified | Uncertain significance (Feb 26, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
TOP1 | protein_coding | protein_coding | ENST00000361337 | 21 | 95670 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 1.20e-8 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.47 | 156 | 411 | 0.379 | 0.0000222 | 5162 |
Missense in Polyphen | 11 | 143.53 | 0.076639 | 1747 | ||
Synonymous | 0.710 | 127 | 138 | 0.923 | 0.00000704 | 1252 |
Loss of Function | 6.57 | 0 | 50.3 | 0.00 | 0.00000304 | 597 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then rotates around the intact phosphodiester bond on the opposing strand, thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component ARNTL/BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the ARNTL/BMAL1 promoter. {ECO:0000250|UniProtKB:Q13472, ECO:0000269|PubMed:14594810, ECO:0000269|PubMed:16033260, ECO:0000269|PubMed:19168442, ECO:0000269|PubMed:22904072, ECO:0000269|PubMed:2833744}.;
- Disease
- DISEASE: Note=A chromosomal aberration involving TOP1 is found in a form of therapy-related myelodysplastic syndrome. Translocation t(11;20)(p15;q11) with NUP98. {ECO:0000269|PubMed:10556215}.;
- Pathway
- Irinotecan Pathway, Pharmacodynamics;Irinotecan Action Pathway;Irinotecan Metabolism Pathway;Post-translational protein modification;SUMOylation of DNA replication proteins;SUMO E3 ligases SUMOylate target proteins;Metabolism of proteins;AndrogenReceptor;SUMOylation;Caspase Cascade in Apoptosis
(Consensus)
Recessive Scores
- pRec
- 0.808
Intolerance Scores
- loftool
- rvis_EVS
- -0.38
- rvis_percentile_EVS
- 27.69
Haploinsufficiency Scores
- pHI
- 0.996
- hipred
- Y
- hipred_score
- 0.831
- ghis
- 0.594
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.956
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Top1
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- DNA replication;DNA topological change;chromatin remodeling;chromosome segregation;circadian rhythm;programmed cell death;viral process;phosphorylation;peptidyl-serine phosphorylation;circadian regulation of gene expression;embryonic cleavage;response to drug
- Cellular component
- nuclear chromosome;P-body;fibrillar center;nucleus;nucleoplasm;nucleolus;DNA topoisomerase complex (ATP-hydrolyzing);replication fork protection complex;protein-DNA complex;perikaryon
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA binding;chromatin binding;double-stranded DNA binding;single-stranded DNA binding;RNA binding;DNA topoisomerase type I activity;protein serine/threonine kinase activity;protein binding;ATP binding;protein domain specific binding;supercoiled DNA binding